Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Antiparkinsonian and neuroprotective effects of novel MAO-B inhibitor

Dec. 1, 2008

S-24795, an alpha7 nAChR partial agonist, may be useful in Alzheimer's disease

Dec. 1, 2008

No difference between CERE-120 and control in phase II clinical trial in PD

Dec. 1, 2008

Alzheimer's Drug Discovery Foundation helps fund Varinel's AD program

Dec. 1, 2008

New agents for treating neurological disorders disclosed in recent patent literature

Dec. 1, 2008

Abbott's V1b vasopressin antagonists, effective in models of anxiety and depression

Nov. 28, 2008

Anxiolytic and analgesic profile of NeuroSearch's novel GABA-A receptor positive modulator

Nov. 28, 2008

Amorfix completes ALS drug discovery program with third milestone

Nov. 28, 2008

H. Lundbeck commences phase II trials for Lu-AE-58054

Nov. 28, 2008

Recent AstraZeneca and Abbott patents report novel analgesic agents

Nov. 28, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...